Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...

Many calves develop pneumonia days before showing symptoms. Lung ultrasounds are helping veterinarians detect the hidden ...

Trevi Therapeutics Investor and Analyst Day May 7, 2026, Midtown New York, New York 10:00 a.m. to 12:00 p.m. ET Representatives: Trevi senior management will be joined by key opinion leaders in ...

A subgroup of patients with SSc who exhibit a severe GI phenotype were associated with longer disease duration, ACA positivity, PAH, and worse quality of life.

GSK’s Exdensur receives China NMPA approval for the treatment of chronic rhinosinusitis with nasal polyps: London, UK Thursday, April 9, 2026, 09:00 Hrs [IST] GSK plc announced ...

Clinical trial designed to evaluate ROC-101 in combination with standard of care therapies including sotatercept NATICK, Mass. /PRNewswire/ -- AllRock Bio, Inc., a ...

The initial public offering (IPO) market showed signs of life for the first time in more than a month as Boston-based Avalyn ...

Investing.com -- Trevi Therapeutics, Inc. (NASDAQ:TRVI) shares fell 10% in after-hours trading Thursday following the company’s announcement of a proposed public offering of common stock.

But some people – such as those living with lung conditions or severe anxiety – experience air hunger frequently in their day ...

Common symptoms like shortness of breath or a lingering cough may seem harmless, but when they persist, they could point to ...

The global pulse oximeter market is expected to expand at a compound annual growth rate (CAGR) of approximately 7% over the ...